Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.01 in the last session, down -2.88% from day before closing price of $1.04. In other words, the price has decreased by -$2.88 from its previous closing price. On the day, 1.92 million shares were traded.
Ratios:
We take a closer look at FATE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.24.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.49 while its Price-to-Book (P/B) ratio in mrq is 0.36.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $0.88. The 50-Day Moving Average of the stock is -26.49%, while the 200-Day Moving Average is calculated to be -64.60%.
Shares Statistics:
A total of 113.93M shares are outstanding, with a floating share count of 98.49M. Insiders hold about 14.06% of the company’s shares, while institutions hold 80.81% stake in the company.
